Sultan Beardsley - PSInvestor.com - PENNY STOCK INVESTOR

February 22, 2025

News Ticker

[ March 16, 2023 ] The Good Flour Corp.: Disrupting an Old, Important Industry with Fantastic, Fresh
Products Uncategorized
[ November 26, 2019 ] Glioblastoma Readout Could be Inflection Point for $DFFN Diffusion Pharmaceuticals BIOTECH STOCKS
[ November 25, 2019 ] AV1 Group (OTC: AVOP) and the Quest for More Info on OMID Holdings CANNABIS STOCKS
[ November 22, 2019 ] ImageProtect (OTC:IMTL) Launches Ad Exchange to Stage Fotofy Revenue Growth — The Start of the Revolution? SUB-PENNY STOCKS
[ November 21, 2019 ] EXCLUSIVE INTERVIEW : Meet ImageProtect’s Matt Goldman Co-CEO of OTC: IMTL (11-21-2019) SUB-PENNY STOCKS

Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis

July 11, 2018 Sultan Beardsley 5

GALT’s upcoming phase 3 trial patient population will be without varices and includes an interim analysis. An interim analysis creates the opportunity for GALT to submit a New Drug Application (NDA) at the 18 month mark […]

Galectin Therapeutics From an Investor Perspective

June 20, 2018 Sultan Beardsley 4

NASH liver disease has been in the headlines quite a bit as key readouts from Madrigal (MDGL) and Galmed (GLMD) teased the markets with their efficacy. Galectin Therapeutics (GALT) which is targeting NASH Cirrhosis has […]

PSInvestor.com